Eton Pharmaceuticals Inc
NASDAQ:ETON
Eton Pharmaceuticals Inc
Operating Income
Eton Pharmaceuticals Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eton Pharmaceuticals Inc
NASDAQ:ETON
|
Operating Income
-$2.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$11.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
14%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$16.2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
12%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$23.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
18%
|
CAGR 10-Years
11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$17B
|
CAGR 3-Years
31%
|
CAGR 5-Years
24%
|
CAGR 10-Years
18%
|
|
Eton Pharmaceuticals Inc
Glance View
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.
See Also
What is Eton Pharmaceuticals Inc's Operating Income?
Operating Income
-2.2m
USD
Based on the financial report for Dec 31, 2024, Eton Pharmaceuticals Inc's Operating Income amounts to -2.2m USD.
What is Eton Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
35%
Over the last year, the Operating Income growth was -83%. The average annual Operating Income growth rates for Eton Pharmaceuticals Inc have been -13% over the past three years , 35% over the past five years .
You don't have any saved screeners yet